Set up your drug discovery breakthroughs for fast-track success.
Even the most promising candidates in any drug discovery program can take 7-10 years and billions of dollars to ultimately achieve FDA approval and reach the market. This may make you wonder whether your drug is eligible for an expedited track. The FDA started the expedited drug program to address the difficulty of getting drugs for rare diseases and serious conditions lacking therapies to market. In this whitepaper, we provide guidance on the four key expedited programs and how working with InVivo Biosystems can position you to take advantage of them.
In this whitepaper, you will learn:
- What Expedited track is best for my drug candidate?
- What preliminary data do I need to apply for each track?
- How will partnering with InVivo Biosystems help prepare my drug for application?
- What are the benefits of pursuing one expedited track or another
Talk with our experts
Learn how InVivo Biosystems can help you acquire the data to prime your drug discovery program for the FDA’s Expedited Tracks.
